candesartan has been researched along with Angina at Rest in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the impact of the angiotensin receptor blocker candesartan on MI and other coronary events in patients with heart failure." | 7.73 | Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. ( Demers, C; Granger, CB; Johansson, PA; McKelvie, RS; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Wang, D; Yusuf, S, 2005) |
| "Candesartan has been reported to reduce cardiovascular events when therapy was started 6 months after PCI with bare-metal stents in patients who survived restenosis." | 6.82 | Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. ( Hokimoto, S; Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Tsujita, K; Yamamoto, N, 2016) |
| "To assess the impact of the angiotensin receptor blocker candesartan on MI and other coronary events in patients with heart failure." | 3.73 | Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. ( Demers, C; Granger, CB; Johansson, PA; McKelvie, RS; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Wang, D; Yusuf, S, 2005) |
| "Candesartan has been reported to reduce cardiovascular events when therapy was started 6 months after PCI with bare-metal stents in patients who survived restenosis." | 2.82 | Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. ( Hokimoto, S; Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Tsujita, K; Yamamoto, N, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakamoto, T | 1 |
| Ogawa, H | 2 |
| Nakao, K | 1 |
| Hokimoto, S | 1 |
| Tsujita, K | 1 |
| Koide, S | 1 |
| Yamamoto, N | 1 |
| Shimomura, H | 1 |
| Matsumura, T | 1 |
| Oshima, S | 1 |
| Kikuta, K | 1 |
| Oka, H | 1 |
| Kimura, K | 1 |
| Matsui, K | 1 |
| Abrahamsson, P | 1 |
| Dobson, J | 1 |
| Granger, CB | 2 |
| McMurray, JJ | 2 |
| Michelson, EL | 2 |
| Pfeffer, M | 1 |
| Pocock, S | 1 |
| Solomon, SD | 1 |
| Yusuf, S | 2 |
| Swedberg, K | 2 |
| Yamaguchi, J | 1 |
| Hagiwara, N | 1 |
| Koyanagi, R | 1 |
| Kasanuki, H | 1 |
| Takagi, A | 1 |
| Mori, F | 1 |
| Nagashima, M | 1 |
| Yagi, M | 1 |
| Demers, C | 1 |
| Pfeffer, MA | 1 |
| Olofsson, B | 1 |
| McKelvie, RS | 1 |
| Ostergren, J | 1 |
| Johansson, PA | 1 |
| Wang, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation[NCT00139386] | Phase 4 | 1,119 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for candesartan and Angina at Rest
| Article | Year |
|---|---|
Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.
Topics: Aged; Angina, Unstable; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular | 2016 |
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin II | 2009 |
Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina, Unstable; Angiotensin II Type 1 Receptor Blocker | 2010 |
1 other study available for candesartan and Angina at Rest
| Article | Year |
|---|---|
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
Topics: Aged; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; | 2005 |